Section 3(d) of the Indian Patents Act limits patentability for new forms or uses of known substances unless enhanced efficacy is proven. The Novartis case illustrates how courts interpret this provision, focusing on therapeutic efficacy rather than mere improved properties.
Read more about Patentability of New Form, Use or Property – Section 3(d)Tag: imatinib mesylate
Patentability and Section 3(d), History of Patent Law in India, Patentability of Imatinib Masylate in Beta Crystalline Form – Novartis Case Abridged by Dr. Kalyan C. Kankanala
This abridged Novartis case by Dr. Kalyan C. Kankanala explains the patentability requirements under Section 3(d) of Indian patent law. It provides a structured analysis of the legal and practical issues surrounding the Imatinib Mesylate patent application.
Read more about Patentability and Section 3(d), History of Patent Law in India, Patentability of Imatinib Masylate in Beta Crystalline Form – Novartis Case Abridged by Dr. Kalyan C. Kankanala